» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome >
VOL. 124 | NO. 122 | Wednesday, June 24, 2009

GlaxoSmithKline Gets Inflammatory Disease Partner

AP

Print | Front Page | Email this story | Comments ()

NEW YORK (AP) - British drug developer GlaxoSmithKline PLC said Tuesday it is collaborating with Chroma Therapeutics Ltd. to develop treatments for inflammatory disorders.

Chroma has the potential to receive $1 billion in milestone and option payments if all four programs under the deal are successful. The partnership will focus on using Chroma's technology to target specific cells at the root of inflammatory diseases such as rheumatoid arthritis.

During each program, Chroma is responsible for research and development activities through completion of clinical proof of concept studies. GlaxoSmithKline has the option to take the compounds to clinical trials.

Shares of GlaxoSmithKline rose 54 cents to $36.23 in Tuesday morning trading.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Sign-Up For Our Free Email Edition
Get the news first with our daily email


 
Blog Get more from The Daily News
Blog News, Training & Events
RECORD TOTALS DAY WEEK YEAR
PROPERTY SALES 57 307 5,073
MORTGAGES 101 483 6,709
FORECLOSURE NOTICES 22 77 1,556
BUILDING PERMITS 0 720 11,979
BANKRUPTCIES 84 341 5,300
BUSINESS LICENSES 36 125 2,061
UTILITY CONNECTIONS 152 594 7,058
MARRIAGE LICENSES 36 117 1,458

Weekly Edition

Issues | About

The Memphis News: Business, politics, and the public interest.